LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression

• Published in: Cancer research (Chicago, Ill.) Vol. 77; no. 20; pp. 5479 - 5490
• Main Authors: Liang, Yi, Ahmed, Musaddeque, Guo, Haiyang, Soares, Fraser, Hua, Junjie T, Gao, Shuai, Lu, Catherine, Poon, Christine, Han, Wanting, Langstein, Jens, Ekram, Muhammad B, Li, Brian, Davicioni, Elai, Takhar, Mandeep, Erho, Nicholas, Karnes, R Jeffrey, Chadwick, Dianne, van der Kwast, Theodorus, Boutros, Paul C, Arrowsmith, Cheryl H, Feng, Felix Y, Joshua, Anthony M, Zoubeidi, Amina, Cai, Changmeng, He, Housheng H
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research, Inc 15.10.2017
• Subjects: Androgen receptors; Androgens; Androgens - metabolism; Animals; Castration; Cell Line, Tumor; Cellular Reprogramming - genetics; Chromatin; Chromosomal Proteins, Non-Histone - biosynthesis; Chromosomal Proteins, Non-Histone - genetics; Chromosomal Proteins, Non-Histone - metabolism; Clonal deletion; Disease Progression; Epigenesis, Genetic; Epigenetics; Heterografts; Histone Demethylases - genetics; Histone Demethylases - metabolism; Humans; Kinesin; Male; Medical treatment; Metastases; Mice; Prostate cancer; Prostatic Neoplasms - embryology; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms, Castration-Resistant - enzymology; Prostatic Neoplasms, Castration-Resistant - genetics; Prostatic Neoplasms, Castration-Resistant - metabolism; Signal Transduction; Therapeutic targets; Transcription; Transfection

Androgen receptor (AR) signaling is a key driver of prostate cancer, and androgen-deprivation therapy (ADT) is a standard treatment for patients with advanced and metastatic disease. However, patients receiving ADT eventually develop incurable castration-resistant prostate cancer (CRPC). Here, we re...